MaxWell Biosystems

Switzerland
Breíl, Grisons, Switzerland, 4058

Company profile

MaxWell Biosystems company profile

MaxWell Biosystems provides solutions to advance basic neuroscience research and accelerate preclinical drug discovery. Its product MaxOne, electrophysiology platform for recording and stimulating electrogenic cells in vitro. It is a CMOS-based high-density microelectrode array with 26,400 electrodes, 1024 low-noise readout channels, and 32 stimulation channels. It allows extracting single cell and network parameters that facilitate phenotypic screening and drug toxicity/efficacy testing.

Business identity

Contact email
[email protected]
Phone number
+41 61 551 10 70
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
4058
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
6
Total equity funding
$4.6M
Last funding
Debt Financing / 2021-12-10
Last equity funding
Series A / $4.5M
Investors
4
Lead investors
3
Founders
1
Articles
11

Founders and investors

Founders

Urs Frey

Lead investors

SensirionTechnology FundVenture Kick

Investors

EISMEASensirionTechnology FundVenture Kick